scholarly journals The effectiveness of tamsulosin hydrochloride with terazosin combination therapy for chronic prostatitis Type-III b

2022 ◽  
Vol 38 (3) ◽  
Author(s):  
Bin Duan ◽  
Xinxi Wang
Keyword(s):  
Combination Therapy ◽  
Chronic Prostatitis ◽  
Treatment Effectiveness ◽  
Control Group ◽  
Therapeutic Effects ◽  
Observation Group ◽  
Clinical Value ◽  
Type Iii ◽  
Creative Commons ◽  
Prostatic Fluid

Objectives: To study the therapeutic effects of combined tamsulosin hydrochloride and terazosin treatment for patients with chronic prostatitis Type-III b. Methods: This study involved 180 patients with chronic prostatitis Type-III b treated between January 2018 and December 2020 conducted at Nanhua Hospital Affiliated to Nanhua University. Patients were randomly divided into two equal groups: one receiving oral terazosin hydrochloride tablets only (control group), and one orally receiving both tamsulosin hydrochloride sustained-release tablets and terazosin hydrochloride tablets (observation group). Outcome measurements included symptom scoring, inflammatory cytokine levels, as well as white blood cell and lecithin body counts in the prostatic fluid. Results: After 30 days of treatment, the observation group showed greater treatment effectiveness (86.67% vs. 73.33%, P<0.05). QLS, USS, PS, and NIH-CPSI symptom scores were lower in the observation group than the control group (P<0.05). No differences in adverse event distribution and incidence were noted. EPS IL-2 increased more in the observation group, while PGE-2, MIP-1α, and MIP-2 decreased more in the observation group. WBC levels decreased more in the observation group, while lecithin body levels increased more in the observation group. Conclusion: The combination of tamsulosin hydrochloride and terazosin for the treatment of patients with chronic prostatitis Type-III b has a significant effect. This approach reduced patient symptoms, lowered inflammatory biomarkers, and generally improved quality of life. This approach appears to have clinical value worthy of future investigation. doi: https://doi.org/10.12669/pjms.38.3.4931 How to cite this:Duan B, Wang X. The effectiveness of tamsulosin hydrochloride with terazosin combination therapy for chronic prostatitis Type-III b. Pak J Med Sci. 2022;38(3):---------. doi: https://doi.org/10.12669/pjms.38.3.4931 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Analysis on Nursing Effect of Octreotide on Acute Pancreatitis

2021 ◽  
Vol 7 (4) ◽  
pp. 300-307
Author(s):  
Chenxia Wu ◽  
Li He
Keyword(s):  
Acute Pancreatitis ◽  
Clinical Symptoms ◽  
Nursing Intervention ◽  
Effective Rate ◽  
Occurrence Rate ◽  
Control Group ◽  
Observation Group ◽  
Clinical Value ◽  
Nursing Satisfaction ◽  
Satisfaction Scale

To explore the clinical value of octreotide therapy and nursing intervention in patients with acute pancreatitis. 120 patients with acute pancreatitis admitted to the Department of Digestive Medicine from June 2018 to August 2019 were selected. Two groups of patients were treated with octreotide. They were randomly divided into observation group (intensive nursing intervention) and control group (routine nursing) with 60 patients in each group. Compared with the control group (81.67%), the total effective rate (93.33%) was higher in the observation group (P<0.05%); After treatment, C reactive protein, lactate dehydrogenase, WBC and hemodiastase of patients in the observation group were better than those in the control group (P<0.05); compared with the control group (18.33%), the occurrence rate of hypoglycemia in the observation group (6.67%) was lower (P<0.05%); At the same time, the Nursing Satisfaction Scale of the observation group (95.00%) was higher than that of the control group (78.33%), (P<0.05%). Patients with acute pancreatitis treated with octreotide and strengthened nursing intervention can obtain more obvious therapeutic effect, so that the clinical symptoms and related laboratory indicators of patients have been significantly improved. At the same time, the clinical value was significant with a lower occurrence rate of hypoglycemia and higher nursing satisfaction scale.

scholarly journals Study on the Effect of Pain Nursing Intervention in ENT Wards

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Baoyi Huang ◽  
Fengmei Xu ◽  
Hongmei Kuang
Keyword(s):  
Quality Of Life ◽  
Severe Pain ◽  
Nursing Intervention ◽  
Control Group ◽  
Nursing Interventions ◽  
Observation Group ◽  
Clinical Value ◽  
Clinical Nursing ◽  
And Control

Objective: To explore the effectiveness of pain nursing interventions for patients in ENT. Methods: The 200 ENT patients admitted from March 2018 to March 2020 were divided into observation group (n=100) and control group (n=100). The control group was used conventional clinical nursing methods, and the observation group received pain nursing intervention as a comparison with the control group. Results: The observation group had 83 cases, 14 cases and 3 cases of mild, moderate and severe pain, respectively, while the control group are of 43 cases, 43cases and 14 cases. Nursing intervention can significantly reduce the pain of patients after otolaryngology surgery, improve the quality of life of patients, and has high clinical value for application.

scholarly journals Analysis of the clinical value of Baogan Lishui decoction and convetional western medicine in treating Hepatitis B cirrhosis refractory ascites

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Huaide Lin
Keyword(s):  
Chinese Medicine ◽  
Hepatitis B ◽  
Combination Treatment ◽  
Western Medicine ◽  
Clinical Effect ◽  
Refractory Ascites ◽  
Control Group ◽  
Observation Group ◽  
Quality And Safety ◽  
Clinical Value

Objective: To investigate the clinical effect of combination treatment of Chinese medicine Baogan Lishui decoction and western medicine on hepatitis B cirrhosis related refactory ascites.Method: Control group was given conventional western medicine therapy while the observation group was given same conventional western medicine therapy with additional of Chinese medicine Baogan Lishui decoction.Result: The total effective of clinical treatment on hepatitis B cirrhosis related refractory ascites in observation group was higher than that of the control group which was 88.89% compared to 71.11%, respectively and it was significant different (p<0.05).Conclusion: The combination treatment of Chinese medicine Baogao Lishui decoction and conventional western medicine can significantly increased the treatment effect on hepatitis B cirrhosis refractory ascites, and thus increases the quality and safety of life.

Amelioration of Extra-articular Effects Associated with Rheumatoid Arthritis Using Anti-arthritic Herbal Formulations

2020 ◽  
pp. 11-20
Author(s):  
Kemzi N. Elechi-Amadi ◽  
Ojoye N. Briggs ◽  
Boma H. Opusunju ◽  
Ebirien-Agana S. Bartimaeus ◽  
Edna O. Nwachuku
Keyword(s):  
Rheumatoid Arthritis ◽  
Combination Therapy ◽  
Day Treatment ◽  
Positive Control ◽  
Negative Control ◽  
Control Group ◽  
Therapeutic Effects ◽  
Herbal Drug ◽  
Standard Drug ◽  
Herbal Formulations

Aim: This study investigated the ability of some herbal formulations to ameliorate extra-articular effects of some herbal formulations used in the management of rheumatoid arthritis in Nigeria. Methodology: Forty-nine (49) female albino Wistar rats were used for this study. They were divided into seven groups: A, B, C, D, E, F and G of seven rats each, with Group A serving as negative control while Group B was a positive control. Groups B, C, D, E, F and G were induced with rheumatoid arthritis by injecting 0.1 ml of Complete Freund's Adjuvant into the right hind paw of each rat. The rats were treated with the standard drug and herbal formulations respectively for 28 days as follows: Group C (treated with a standard drug, Celebrex), Group D (treated with the herbal drug, Jointeez), Group E (treated with a herbal drug, Arthropower), Group F (treated with combination therapy of Jointeez and Celebrex) and Group G (treated with combination therapy of Arthropower and Celebrex). At the end of the 28-day treatment period, the rats were anaesthetized with chloroform and sacrificed through puncture of the jugular vein. Five millilitres (5 ml) of blood samples were put into plain bottles for the analysis of biochemical parameters and 3 ml into K3EDTA bottles for haematological analysis. The lipid parameters were analysed using Mindray autoanalyzer while haematological parameters were determined using Sysmex haematology auto analyzer. Results: Total cholesterol (p<0.001), HDL (p=0.005) and LDL (p=0.004) were significantly reduced in the treated rats compared to the positive control group. Conversely, Packed Cell Volume (p<0.001) and Haemoglobin levels (p<0.001) were significantly reduced in the positive control rats compared to the treated rats. However, Total WBC count was significantly higher in the positive control rats than in the treated rats (p=0.001). The combination therapies used in this study did not offer a significantly different therapeutic advantage over the monotherapies used. The herbal formulations gave therapeutic effects on the extra-articular effects similar to that obtained from the orthodox drug used in this study.  Conclusion: The herbal formulations can be used as alternative regimens for rheumatoid arthritis. It is recommended that herbal formulations be considered for integration into our healthcare system for the management of rheumatoid arthritis.

scholarly journals Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function

2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Kun Mi ◽  
Qiang Guo ◽  
Bao-yan Xu ◽  
Man Wang ◽  
Hao Bi
Keyword(s):  
Cognitive Function ◽  
Hyperbaric Oxygen ◽  
Depression Scale ◽  
Control Group ◽  
Hamilton Depression Scale ◽  
Observation Group ◽  
Creative Commons ◽  
Significant Difference ◽  
Hamd Score ◽  
Icd 10

Objective: To investigate the efficacy of hyperbaric oxygen (HBO) combined with escitalopram in patients with depression and its effect on cognitive function. Methods: From 2016 to 2018, seventy patients with depression aged 18-65 years treated in Affiliated Hospital of Hebei University were selected. Seventy patients with depression meeting the diagnostic criteria of ICD-10 were selected and randomly divided into control group and observation group using a random number table, with 35 patients in each group. The control group was treated with escitalopram, while the observation group was additionally treated with HBO on this basis. The patients were assessed using the Hamilton Depression Scale (HAMD) and Montreal Cognitive Assessment Scale (MoCA) before treatment and two, four and six weeks after treatment. Results: Two weeks after treatment, HAMD score showed a statistically significant difference between the two groups (P < 0.05). No statistically significant differences were found in HAMD score between the two groups four and six weeks after treatment (P > 0.05). Four and six weeks after treatment, MoCA score presented statistically significant differences between the two groups (P < 0.05). Conclusion: Escitalopram combined with HBO in the treatment of depression presents rapid efficacy and a certain effect in improving cognitive function. doi: https://doi.org/10.12669/pjms.37.4.3993 How to cite this:Mi K, Guo Q, Xu BY, Wang M, Bi H. Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function. Pak J Med Sci. 2021;37(4):---------. doi: https://doi.org/10.12669/pjms.37.4.3993 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit

2021 ◽  
Vol 24 (2) ◽  
pp. 139-143
Author(s):  
Mohsen Farrokhpour ◽  
Nader Rezaie ◽  
Najmeh Moradi ◽  
Fatemeh Ghaffari Rad ◽  
Shirin Izadi ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Combination Therapy ◽  
Clinical Symptoms ◽  
Observational Research ◽  
Control Group ◽  
Therapeutic Effects ◽  
Significant Difference ◽  
Intravenous Gammaglobulin ◽  
Underlying Diseases

Background: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU). Methods: In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine + lopinavir/ritonavir or sofosbuvir or atazanavir ± ribavirin). The cases were grouped as controls (n = 43), infliximab (n = 27), IVIg (n = 23) and combination (n = 11). Results: There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of cases was 72.42 (16.06) in the control group, 64.52 (12.965) in IVIg, 63.40 (17.57) in infliximab and 64.00 (11.679) in combination therapy; (P = 0.047, 0.031 and 0.11, respectively). Also, 37% in the infliximab group, 26.1% in IVIg, 45.5% in combination therapy, and 62.8% in the control group expired (all P < 0.05). Hazard ratios were 0.31 in IVIg (95% CI: 0.12-0.76, P = 0.01), 0.30 in infliximab (95% CI: 0.13-0.67, P = 0.004), 0.39 in combination therapy (95% CI: 0.12-1.09, P = 0.071). Conclusion: According to the findings of this study, it seems that infliximab and IVIg, alone or together, in patients with severe COVID-19 disease can be considered an effective treatment.

scholarly journals Cloud Computing into Respiratory Rehabilitation Training-Assisted Treatment of Patients with Pneumonia

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Yan Yu
Keyword(s):  
Cloud Computing ◽  
Control Group ◽  
Therapeutic Effects ◽  
Observation Group ◽  
Effect Analysis ◽  
Rehabilitation Training ◽  
Computing Model ◽  
Therapy Program ◽  
Medical University ◽  
Respiratory Rehabilitation

In order to study the therapeutic effect of respiratory rehabilitation training on patients with pneumonia, this paper proposes an integrated adjuvant therapy program based on the cloud computing model. A total of 60 pneumonia patients admitted to Zhujiang Hospital of Southern Medical University from January to July 2020 were selected as the research objects and Southern Medical University pneumonia patients as the research object, to be evenly divided into two groups, each group of 30 people. The control group was treated with conventional anti-infection treatment, and the observation group was treated with supplementary respiratory rehabilitation training on the basis of conventional treatment. The therapeutic effects of the two groups were compared. The results showed that the absorption time of lung lesions was (9.17 ± 3.46) days in the observation group and (13.97 ± 3.07) days in the control group, and the difference between the two groups was statistically significant (t = 5.683, P < 0.001 ). Respiratory therapy based on the cloud computing model has the characteristics of integration and extensibility, which can be effectively applied to the treatment effect analysis of patients with pneumonia and is of great significance for the effective analysis of patients’ blood gas indexes and lung function indexes.

scholarly journals Analysis on the Effects of Shensong Yangxin Capsules and Amiodarone on Heart Rate Variability Indices and Inflammatory Factors in Patients with Arrhythmia

2021 ◽  
Vol 5 (3) ◽  
Author(s):  
Yongjie Wang ◽  
Hongxing Zhang ◽  
Wangbo Cao
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Adverse Reactions ◽  
Inflammatory Factors ◽  
Control Group ◽  
Therapeutic Effects ◽  
Observation Group ◽  
Research Subjects ◽  
Combined Use ◽  
Better Than

Objective: To study the effects of Shensong Yangxin capsules and amiodarone on heart rate variability indexes and inflammatory factors in the treatment of patients with arrhythmia. Methods: The research subjects were selected patients with arrhythmia admitted in our hospital's department from October 2018 to October 2019, and a total of 70 patients were divided into two groups. 35 subjects in the control group were treated with amiodarone alone, and 35 subjects in the observation group were treated with Shensongyangxin capsule in combination with amiodarone for comparisons in treatment effects, heart rate variability indices, inflammatory factors, and adverse reactions. Results: After observation, the treatment efficiency in the observation group was higher than that in the control group (P<0.05). Before treatment, there was no difference in heart rate variability indices between the two groups (P>0.05), after treatment, the improvement in patients of the observation group was better than that of the control group (P<0.05). After treatment, the inflammatory factors of the two groups of patients decreased, and the indicators of the observation group were comparably lower than those of the control group (P<0.05). In the comparison of adverse reactions, the observation group showed a lower incidence of adverse reactions after treatment than the control group (P<0.05). Conclusion: In the treatment of patients with arrhythmia, the combined use of Shensong Yangxin capsules and amiodarone has more significant therapeutic effects, which can effectively improve the patient's heart rate variability indices, reduce the inflammatory factors, and relieve the symptoms in patients. The incidence of adverse reactions is low and the safety is quite high, therefore it has great value in clinical applications.

scholarly journals Budesonide/Fomoterol in combination with Montelukast in the treatment of Bronchial Asthma

2020 ◽  
Vol 36 (7) ◽  
Author(s):  
Xiaoxia Dai ◽  
Tao Feng ◽  
Xuejuan Zhang ◽  
Kaishu Li
Keyword(s):  
Symptom Score ◽  
Bronchial Asthma ◽  
Persistent Asthma ◽  
Inflammatory Factors ◽  
Control Group ◽  
Efficacy Rate ◽  
Observation Group ◽  
Creative Commons ◽  
The Difference ◽  
Open Access Article

Objective: To analyze the clinical effect of budesonide/fomoterol combined with montelukast in the treatment of chronic persistent asthma. Methods: Ninety-four patients with asthma who came to our hospital for treatment from April 2017 to April 2019 were randomly divided into control group and observation group, with 47 patients in each group. The control group was treated with budesonide/formoterol, and the observation group was treated with montelukast on the basis of the control group. The treatment effect of the two groups was observed and compared. Results: The total efficacy rate of the observation group was significantly higher than that of the control group (P<0.05); the daytime symptom score and nighttime symptom score of the observation group were significantly higher than those of the control group (P<0.05). The pulmonary function indexes of the two groups after treatment were significantly higher than that before treatment, and the improvement of the observation group was more significant (P<0.05); the FeNO and EO levels of the observation group after treatment were superior to those of the control group, and the difference was statistically significant (P<0.05). Conclusion: Budesonide/formoterol powder inhalation combined with montelukast can effectively improve the lung function, reduce the level of inflammatory factors, and accelerate the regression of symptoms in the treatment of chronic persistent asthma. It is worth clinical application. doi: https://doi.org/10.12669/pjms.36.7.2018 How to cite this:Dai X, Feng T, Zhang X, Li K. Budesonide/Fomoterol in combination with Montelukast in the treatment of Bronchial Asthma. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2018 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Clinical effect and safety evaluation of different dosage of Rituximab combined with Cyclophosphamide in treatment of refractory immune Thrombocytopenia

2019 ◽  
Vol 36 (2) ◽  
Author(s):  
Zhibin Wang ◽  
Yu Ren ◽  
Weibo Huang ◽  
Haiying Yao
Keyword(s):  
Immune Thrombocytopenia ◽  
Clinical Effect ◽  
Statistical Significance ◽  
Safety Evaluation ◽  
Occurrence Rate ◽  
Control Group ◽  
Observation Group ◽  
Clinical Safety ◽  
Creative Commons ◽  
Before And After

Objective: To discuss clinical effect of different dosage of rituximab combined with cyclophosphamide in treatment of refractory immune thrombocytopenia (rITP). Method: This study was conducted at Department of Hematopathology in XX Hospital from January 2016 to January 2018. In this study. Seventy-eight patients with rITP were selected as the objects, divided into observation group (39 cases) and control group (39 cases) according to random number table. Patients in the control group were treated with conventional rituximab and cyclophosphamide, while the observation group received low-dose rituximab. The same amount of cyclophosphamide was used in the two groups. The statistics of clinical effect, recurrence rate, untoward effect and Laboratory inspection of both groups were made before and after the treatment. Results: Compared with the control group, the total occurrence rate of side effects in the observation group decreased significantly; the level of IgM and CD20+ in the observation group also decreased significantly, while. The level of IgA, IgG, CD3+ and CD4+ rose significantly (P<0.05). The differences in the level of Th1, TNF-a, IL-18 and Sc5b-9 had statistical significance before and after the treatment (P<0.05). Conclusion: Rituximab combined with cyclophosphamide has the definite curative effect on rITP. The small dosage of rituximab combined with cyclophosphamide has higher clinical safety in the treatment. doi: https://doi.org/10.12669/pjms.36.2.1168 How to cite this:Wang Z, Ren Y, Li M, Huang W, Yao H. Clinical effect and safety evaluation of different dosage of Rituximab combined with Cyclophosphamide in treatment of refractory immune Thrombocytopenia. Pak J Med Sci. 2020;36(2):---------.   doi: https://doi.org/10.12669/pjms.36.2.1168 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document